$SWTX
SpringWorks Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000177342724000025 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $49.30M $59.73M $0.00
YoY Change
Cost Of Revenue $3.341M $2.453M $0.00
YoY Change
Gross Profit $45.96M $57.28M $0.00
YoY Change
Gross Profit Margin 93.22% 95.89%
Selling, General & Admin $61.60M $57.84M $46.99M
YoY Change 32.33% 23.09% 51.64%
% of Gross Profit 134.03% 100.98%
Research & Development $42.30M $44.36M $35.86M
YoY Change 12.93% 23.72% -5.7%
% of Gross Profit 92.03% 77.45%
Depreciation & Amortization $878.0K $844.0K $382.0K
YoY Change 79.18% 120.94% 101.05%
% of Gross Profit 1.91% 1.47%
Operating Expenses $103.9M $102.2M $82.85M
YoY Change 23.69% 23.35% 20.06%
Operating Profit -$57.94M -$44.92M -$82.85M
YoY Change -31.03% -45.78% 20.06%
Interest Expense $4.407M $5.002M $5.030M
YoY Change -5.02% -0.56% -33633.33%
% of Operating Profit
Other Income/Expense, Net $6.216M $6.778M $5.828M
YoY Change 11.28% 16.3% 1574.71%
Pretax Income -$53.53M -$39.92M -$77.93M
YoY Change -32.62% -48.78% 12.86%
Income Tax
% Of Pretax Income
Net Earnings -$53.53M -$39.92M -$77.93M
YoY Change -32.61% -48.77% 12.85%
Net Earnings / Revenue -108.58% -66.83%
Basic Earnings Per Share -$0.72 -$0.54 -$1.25
Diluted Earnings Per Share -$0.72 -$0.54 -$1.25
COMMON SHARES
Basic Shares Outstanding 74.27M shares 74.09M shares 62.52M shares
Diluted Shares Outstanding 74.26M shares 74.12M shares 62.46M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $376.6M $383.9M $476.7M
YoY Change -10.84% -19.47% 42.5%
Cash & Equivalents $84.46M $79.90M $115.0M
Short-Term Investments $292.2M $304.0M $361.7M
Other Short-Term Assets $15.69M $15.22M $7.194M
YoY Change 56.94% 111.52% -3.54%
Inventory $9.826M $7.718M
Prepaid Expenses
Receivables $32.97M $24.50M
Other Receivables $0.00 $0.00
Total Short-Term Assets $435.1M $431.3M $483.9M
YoY Change 0.63% -10.87% 41.49%
LONG-TERM ASSETS
Property, Plant & Equipment $19.34M $18.21M $25.00M
YoY Change -7.59% -27.18% 171.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $5.580M $7.389M $4.814M
YoY Change 47.27% 53.49% -24.28%
Other Assets $20.70M $15.38M $3.613M
YoY Change 494.32% 325.8% 34.46%
Total Long-Term Assets $173.8M $186.0M $33.43M
YoY Change 392.66% 456.44% 39.75%
TOTAL ASSETS
Total Short-Term Assets $435.1M $431.3M $483.9M
Total Long-Term Assets $173.8M $186.0M $33.43M
Total Assets $608.9M $617.3M $517.3M
YoY Change 30.2% 19.33% 41.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.654M $7.889M $3.454M
YoY Change 74.07% 128.4% 57.64%
Accrued Expenses $59.73M $45.65M $36.09M
YoY Change 48.1% 26.49% 12.05%
Deferred Revenue $0.00 $0.00 $2.364M
YoY Change -100.0% -100.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $70.61M $54.50M $41.91M
YoY Change 40.43% 30.04% 20.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $5.684M $6.101M $23.98M
YoY Change -74.74% -74.56% 354.9%
Total Long-Term Liabilities $5.684M $6.101M $23.98M
YoY Change -74.74% -74.56% 354.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.61M $54.50M $41.91M
Total Long-Term Liabilities $5.684M $6.101M $23.98M
Total Liabilities $76.30M $60.60M $65.89M
YoY Change 4.87% -8.02% 63.96%
SHAREHOLDERS EQUITY
Retained Earnings -$1.076B -$1.022B -$721.3M
YoY Change 34.37% 41.74% 70.36%
Common Stock $7.000K $7.000K $6.000K
YoY Change 16.67% 16.67% 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $532.6M $556.7M $451.4M
YoY Change
Total Liabilities & Shareholders Equity $608.9M $617.3M $517.3M
YoY Change 30.2% 19.33% 41.38%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$53.53M -$39.92M -$77.93M
YoY Change -32.61% -48.77% 12.85%
Depreciation, Depletion And Amortization $878.0K $844.0K $382.0K
YoY Change 79.18% 120.94% 101.05%
Cash From Operating Activities -$25.38M -$41.79M -$47.81M
YoY Change -49.7% -12.59% 22.37%
INVESTING ACTIVITIES
Capital Expenditures $1.847M $12.23M $3.088M
YoY Change -48.98% 295.89% -222.3%
Acquisitions
YoY Change
Other Investing Activities $30.50M $12.51M $63.84M
YoY Change -20.21% -80.4% 118.03%
Cash From Investing Activities $28.65M $289.0K $60.76M
YoY Change -17.2% -99.52% 127.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.291M 3.371M -342.0K
YoY Change -637.92% -1085.67% 288.64%
NET CHANGE
Cash From Operating Activities -25.38M -41.79M -47.81M
Cash From Investing Activities 28.65M 289.0K 60.76M
Cash From Financing Activities 1.291M 3.371M -342.0K
Net Change In Cash 4.560M -38.13M 12.60M
YoY Change -128.32% -402.55% -201.62%
FREE CASH FLOW
Cash From Operating Activities -$25.38M -$41.79M -$47.81M
Capital Expenditures $1.847M $12.23M $3.088M
Free Cash Flow -$27.23M -$54.01M -$50.90M
YoY Change -49.66% 6.12% 39.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2023Q2 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2024#ProductMember
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2024Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
19547000 usd
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 usd
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 usd
CY2024Q2 us-gaap Revenues
Revenues
59733000 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46994000 usd
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
61192000 usd
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 usd
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
19547000 usd
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 usd
CY2024Q2 us-gaap Revenues
Revenues
59733000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
61192000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2024Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
19547000 usd
CY2023Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 usd
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 usd
CY2024Q2 us-gaap Revenues
Revenues
59733000 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
57839000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46994000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44362000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62464081 shares
us-gaap Revenues
Revenues
80739000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46994000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44362000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35858000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97984000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69382000 usd
CY2024Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
104654000 usd
CY2023Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
82852000 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
219591000 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
160551000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44921000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-82852000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-138852000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-160551000 usd
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
6778000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
14349000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
11385000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6778000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5828000 usd
CY2024Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1776000 usd
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-901000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.43
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74121014 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74121014 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62464081 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62464081 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62360651 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62360651 shares
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44362000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35858000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97984000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69382000 usd
CY2024Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
104654000 usd
CY2023Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
82852000 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
219591000 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
160551000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44921000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-82852000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-138852000 usd
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
6778000 usd
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
5828000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
14349000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
11385000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6778000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5828000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11385000 usd
CY2024Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1776000 usd
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-901000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.43
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74121014 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74121014 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62464081 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62464081 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73944809 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73944809 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62360651 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62360651 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-39919000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77925000 usd
us-gaap Net Income Loss
NetIncomeLoss
-151345000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-407000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-190000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1711000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
415000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-407000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1711000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
415000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40326000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78115000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129015000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
506924000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35858000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97984000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69382000 usd
CY2024Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
104654000 usd
CY2023Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
82852000 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
219591000 usd
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
160551000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-44921000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-82852000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-138852000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-160551000 usd
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
6778000 usd
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
5828000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
14349000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6778000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5828000 usd
CY2024Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1776000 usd
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-901000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2179000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.43
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74121014 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74121014 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62464081 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62464081 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73944809 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73944809 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62360651 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62360651 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77925000 usd
us-gaap Net Income Loss
NetIncomeLoss
-151345000 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-407000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-190000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1711000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
415000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-407000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1711000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40326000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78115000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129015000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
506924000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22974000 usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62464081 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73944809 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73944809 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62360651 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
62360651 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77925000 usd
us-gaap Net Income Loss
NetIncomeLoss
-151345000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-190000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1711000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
415000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-407000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1711000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
415000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40326000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-78115000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-129015000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-150930000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22974000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
352000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77925000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22974000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
352000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77925000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
567440000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26245000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4290000 usd
CY2024Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
919000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-407000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
556730000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
558192000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
11250000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
2800000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
159232000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
212612000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
202021000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4615000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-354000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
837000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
208000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4835000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3069000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-19547000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
swtx Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-1059000 usd
swtx Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-446000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120720000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6065000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000 usd
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
352000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-190000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-77925000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
451441000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
567440000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26245000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4290000 usd
CY2024Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
919000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-407000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
556730000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
558192000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
46369000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
18574000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4615000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2540000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
837000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
208000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4835000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3069000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-19547000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
swtx Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-1059000 usd
swtx Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-446000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120720000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1552000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6065000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
11250000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
8235000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
2800000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
159232000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
212612000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
380837000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21752000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
159360000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
567440000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26245000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4290000 usd
CY2024Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
919000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-407000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-39919000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
556730000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
558192000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
18574000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4615000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2540000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-354000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
208000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
360000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4835000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-8528000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3069000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-19547000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
swtx Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-1059000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-120720000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-109629000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1552000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6065000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
8235000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
2800000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
159232000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
202021000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
380837000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
159360000 usd
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
662600000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21752000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
159360000 usd
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
662600000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses, valuation of equity-based compensation awards and variable consideration and other relevant inputs impacting the gross and net revenue recognition. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.</span></div>
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
442555000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
521000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
442035000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1191000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2024Q2 swtx Equity Method Investments Purchase Obligation Value
EquityMethodInvestmentsPurchaseObligationValue
12400000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses, valuation of equity-based compensation awards and variable consideration and other relevant inputs impacting the gross and net revenue recognition. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.</span></div>
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
442555000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
521000 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
442035000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
485344000 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
486535000 usd
CY2024Q2 swtx Equity Method Investments Purchase Obligation Value
EquityMethodInvestmentsPurchaseObligationValue
12400000 usd
CY2024Q2 swtx Accrued Milestone
AccruedMilestone
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses, valuation of equity-based compensation awards and variable consideration and other relevant inputs impacting the gross and net revenue recognition. Management bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. On an ongoing basis, management evaluates its estimates, and adjusts those estimates and assumptions when facts or circumstances change. Changes in estimates are recorded in the period in which they become known.</span></div>
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
442555000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
521000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
485344000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
486535000 usd
CY2024Q2 swtx Equity Method Investments Purchase Obligation Value
EquityMethodInvestmentsPurchaseObligationValue
12400000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15034000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26047000 usd
CY2024Q2 swtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
14382000 usd
CY2023Q4 swtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
15129000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16237000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15034000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26047000 usd
CY2024Q2 swtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
14382000 usd
CY2023Q4 swtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
15129000 usd
CY2024Q2 swtx Accrued Milestone
AccruedMilestone
0 usd
CY2023Q4 swtx Accrued Milestone
AccruedMilestone
11250000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16237000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13143000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45653000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
65569000 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26245000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56707000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15358604 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13492021 shares
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
15034000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26047000 usd
CY2024Q2 swtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
14382000 usd
CY2023Q4 swtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
15129000 usd
CY2024Q2 swtx Accrued Milestone
AccruedMilestone
0 usd
CY2023Q4 swtx Accrued Milestone
AccruedMilestone
11250000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
16237000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13143000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45653000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
65569000 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26245000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22974000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15358604 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13492021 shares
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13143000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45653000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
65569000 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26245000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22974000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56707000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15358604 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13492021 shares
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001773427-24-000025-index-headers.html Edgar Link pending
0001773427-24-000025-index.html Edgar Link pending
0001773427-24-000025.txt Edgar Link pending
0001773427-24-000025-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
swtx-20240630.htm Edgar Link pending
swtx-20240630.xsd Edgar Link pending
swtx-20240630xex311.htm Edgar Link pending
swtx-20240630xex312.htm Edgar Link pending
swtx-20240630xex321.htm Edgar Link pending
swtx-20240630xex322.htm Edgar Link pending
swtx-20240630_cal.xml Edgar Link unprocessable
swtx-20240630_def.xml Edgar Link unprocessable
swtx-20240630_lab.xml Edgar Link unprocessable
swtx-20240630_pre.xml Edgar Link unprocessable
swtx-20240630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable